.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, occupying the leading science spot at Sanofi.Quigley will start Sept. 30 as the French Big Pharma's chief clinical officer as well as worldwide head of investigation, Sanofi said to Ferocious Biotech in an emailed statement.Quigley is actually replacing Frank Nestle, M.D., who left behind Sanofi this springtime surrounded by a worldwide overhaul of the business's R&D device. Nestle, that devoted 8 years along with the pharma, jumped over to Deerfield Monitoring, where he presently works as a partner on the therapies team and also chief executive officer of the agency's therapeutic exploration as well as development functions.
Quigley is going to join Sanofi from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile. He is actually presently detailed as the provider's founder, head of state and also CEO.Due to the fact that August 2021, Quigley has served as a venture companion at SV Wellness Investors, a health care fund supervisor along with existing assets in biotechs such as BioAge, Cerevance, Dualitas Rehabs and also Nimbus Therapies, among others. Quigley in the past kept the best area at Dualitas, a biotech that stays in stealth, depending on to STAT.The prospective Sanofi innovator additionally recently helmed Therini Bio, an immunotherapy biotech functioning to build procedures for neurodegenerative illness steered by general problems.Before devoting the last couple of years in biotech, Quigley possesses an even longer track record in Large Pharma, very most recently functioning as Gilead's elderly bad habit president of investigation the field of biology up until the summer of 2021. Prior to that, he clocked in much more than 4 years around numerous management tasks at Bristol Myers Squibb and also worked as a clinical director at Johnson & Johnson's Janssen upper arm just before that.Sanofi pointed out Quigley's purpose in his brand new part will be actually to "maximize our chance of results with optimal collaborations across our institution and past, delivering best-in-class advancement in addition to creating and also sourcing new industry-leading skill along with a commitment to variety," according to an inner memo gotten through STAT.